/PRNewswire/ The "Cell Line Development Services Global Market - Forecast To 2030" report has been added to ResearchAndMarkets.com s offering. The cell line.
/PRNewswire/ The "Cell Line Development Services Global Market - Forecast To 2030" report has been added to ResearchAndMarkets.com s offering. The cell line.
Last week, Sandoz announced that it submitted a Biologic License Application (BLA) for a proposed biosimilar trastuzumab (150 mg, for intravenous use) to the FDA. According to the press.
Submission is supported by comprehensive package of analytical, pre-clinical and clinical data, proposed biosimilar trastuzumab developed by EirGenix, Inc.Breast cancer is one of most common types of cancer